B of A Securities Maintains Buy on Arrowhead Pharma, Raises Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry has maintained a Buy rating on Arrowhead Pharma (NASDAQ:ARWR) and increased the price target from $29 to $37, indicating a positive outlook on the company's stock.
January 02, 2024 | 4:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arrowhead Pharma's stock rating has been reaffirmed as Buy by B of A Securities, with a raised price target from $29 to $37, suggesting confidence in the company's future performance.
The increase in price target by a reputable analyst like Jason Gerberry typically signals a strong conviction in the company's growth potential and financial health. This can lead to increased investor confidence and a potential rise in stock price in the short term as the market reacts to the positive endorsement.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100